» Articles » PMID: 26163354

Surgical Outcomes of Patients With Stage III Thymoma in the Japanese Nationwide Database

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2015 Jul 12
PMID 26163354
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the clinical characteristics and therapeutic outcomes of patients who underwent surgery for stage III thymoma in Japan.

Methods: Using the Japanese nationwide database, which contains the records of 2,835 patients with thymic epithelial tumors who underwent treatment between 1991 and 2010, we extracted and analyzed the records of those who underwent surgery for stage III thymoma.

Results: A total of 310 patients (170 males, 140 females; median age, 58 years) were analyzed. Involved sites were the lung in 194 (62.6%), the pericardium in 151 (48.7%), the great vessels in 126 (40.6%), the phrenic nerve in 84 (27.1%), and the chest wall in 7 (2.3%). Complete resection (R0) was achieved in 247 (79.7%) cases. Induction therapies were administered to 42 (13.5%) patients, and postoperative therapies were administered to 147 (47.4%). In R0 cases, 68 (27.5%) experienced recurrence. The pleural space was the most frequent site of recurrence (46; 18.6%). The 10-year overall and disease-free (in R0) survival rates were 80.2% and 51.6%, respectively. Multivariate analyses revealed that age (p = 0.002), male sex (p = 0.017), induction therapy (p < 0.001), and type B histology (p = 0.037) were independent adverse predictors for overall survival. Chest wall invasion was the only independent adverse predictor for disease-free survival, although the factor analysis was marginal for overall survival.

Conclusions: The outcomes of surgery for patients with stage III thymoma were favorable unless chest wall invasion was present; however, the role of complete resection and appropriate multimodal treatment plan require further investigation.

Citing Articles

Investigating the impact of tumor size on survival outcomes in thymoma and thymic carcinoma patients using the SEER database.

Yin Y, Wang W, Tang M, Liu W Sci Rep. 2024; 14(1):27680.

PMID: 39533067 PMC: 11557901. DOI: 10.1038/s41598-024-79186-5.


Narrative review of indication and management of induction therapy for thymic epithelial tumors.

Ajimizu H, Sakamori Y Mediastinum. 2024; 8:44.

PMID: 39161586 PMC: 11330911. DOI: 10.21037/med-23-30.


Re-evaluation and operative indications after induction therapy for thymic epithelial tumors.

Yamada Y, Hamaji M, Okada H, Takahagi A, Ajimizu H, Koyasu S Mediastinum. 2024; 8:43.

PMID: 39161585 PMC: 11330912. DOI: 10.21037/med-23-70.


Surgical outcomes of patients with locally advanced thymic epithelial tumor undergoing induction therapy followed by surgery: a narrative review.

Shimada Y, Ohira T, Ikeda N Mediastinum. 2024; 8:42.

PMID: 39161581 PMC: 11330909. DOI: 10.21037/med-23-57.


Surgical treatment of thymic epithelial tumors: a narrative review.

Agrafiotis A, Berzenji L, Koyen S, Vermeulen D, Winthagen R, Hendriks J Mediastinum. 2024; 8:32.

PMID: 38881810 PMC: 11176987. DOI: 10.21037/med-23-44.